Article thumbnail

Commentary: Aspirin is safe and effective for CHD primary prevention where coronary event risk is greater than 1.5% per year

By TW Meade
Year: 2001
OAI identifier:
Provided by: LSHTM Research Online

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1996). A new short form individual quality of life measure (SEIQoLDW): application in a cohort of individuals with HIV/AIDS. BMJ
  2. (1992). A: Hormone replacement therapy and cardiovascular disease. Br Med Bull
  3. and Drug Administration: The estrogen and progestin dilemma: new advice, labelling guidelines.
  4. (1995). AT: Estrogens, the immune response and autoimmunity. Clin Exp Rheumatology
  5. (1997). C: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease. The Baltimore Longitudinal Study of Aging. Neurology
  6. (1996). Cauley JA: Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Arch Intern Med
  7. (2004). Climacteric
  8. (1991). Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med
  9. (1997). Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet
  10. (2003). Committee on Safety of Medicines: HRT:update on the risk of breast cancer and long term safety. Current Problems in Pharmacovigilanc
  11. (1996). Council's General Practice Research Framework: Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ
  12. (1996). Effect of oestrogen during menopause on risk and age at outset of Alzheimer's disease. Lancet
  13. (1997). Effects of estrogen use on lens transmittance in postmenopausal women. Ophthamology
  14. (1996). Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol
  15. (1990). EUROQOL: A new facility for the measurement of health related quality of life. Health Policy
  16. (2002). for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA
  17. (2003). for the Womens Health Initiative investigators: Effects of estrogen plus progestin on health related quality of life.
  18. (1991). Goldar D: Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
  19. (1995). Health-related behaviours and their correlates in a general population sample of 45-year old women. Psychology and Health
  20. (1997). Hennekens CH, Speizer FE: Postmenopausal hormone therapy and mortality.
  21. (1991). Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease: Ten year follow-up from the Nurses' Health Study.
  22. (1996). Hennekens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet
  23. (1987). Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.
  24. (1996). Hormone replacement therapy and breast cancer: an overview.
  25. (2001). Horwitz RI: A clinical trial of estrogen -replacement therapy after ischemic stroke.
  26. (1995). Howe GR: Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiology, Biomarkers & Prevention
  27. (1996). Jr: Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol
  28. (1997). KD: The association between estrogen status and alveolar bone density changes in postmenopausal women with a history of periodontitis. Periodontology
  29. (1996). KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet
  30. (1979). Knapp RC: Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet Gynecol
  31. (1988). L: Validation study of WOMAC: a health ststus instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. The Journal of Rheumatology
  32. (1994). LL: Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc
  33. (2002). MacDermid JC: Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage
  34. (1996). MM: Case control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet
  35. (1994). Modelling Survival Data in Medical Research Chapman and Hall;
  36. (2004). Mortality associated with hormone replacement therapy in younger and older women.
  37. (1997). Oliart AD: Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ
  38. (1996). Parazzini F: Oral contraceptives, hormone replacement therapy and risk of colorectal cancer.
  39. (2002). Prevalence of Dementia in Users of Hormone Replacement Therapy as Defined by Prescription.
  40. (1980). Randomised controlled trials and retrospective controls. BMJ
  41. (1996). S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet
  42. (2000). Sandset PM: Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis
  43. (1996). SC: Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales. Quality of Life Research
  44. (1992). Sherbourne C: The MOS 36-item short-form health survey (SF 36). 1. Conceptual framework and item selection. Medical Care
  45. (1992). Spinato S: Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surgery, Oral Medicine, Oral Pathology
  46. (1992). SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med
  47. (2000). Stampfer MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med
  48. (2001). Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: a prospective, observational study. Ann Intern Med
  49. (2003). Study collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet
  50. (1996). Sudden sensorineural deafness and hormone replacement therapy.
  51. (1995). The Benefits of Estrogen Replacement Therapy on Oral Health. Arch Int Med
  52. (1977). The CES-D Scale: A self-report depression scale for research in the general population. Applied Psychological Measurement
  53. (2003). The European Agency for the Evaluation of Medical Products: EMEA public statement on recent publications regarding hormone replacement therapy. [ press/pus/3306503en.pdf]. 3
  54. (1995). The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum
  55. (1996). The MRC long-term randomised controlled trial of hormone replacement therapy: Background, design and objectives.
  56. (1998). The Women's Health Initiative Study Group: Design of the Women's Health Initiative Clinical trial and Observational Study. Controlled Clinical Trials
  57. (1992). The women's health questionnaire: A measure of mid-aged women's perceptions of their emotional and physical health. Psychology and Health
  58. (1995). The Writing Group for the PEPI trial: Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women.
  59. (1991). TW: Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. BMJ
  60. (2002). WISDOM: history and early demise – was it inevitable? Climacteric
  61. (2004). Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomised Controlled Trial. JAMA